Adipocyte-derived Exosomal miRNAs: A Novel Mechanism for Obesity-Related Disease

Sarah C Ferrante1, Evan P Nadler1,2,3, Dinesh K Pillai1,4,5, Monica J Hubal1,2, Zuyi Wang1, Justin M Wang1, Heather Gordish-Dressman1, Emily Koeck2, Samantha Sevilla2, Andrew A Wiles1, and Robert J Freishtat1,4,6,*

1Department of Integrative Systems Biology, Children’s National Medical Center, Washington, DC, USA
2Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National Medical Center, Washington, DC, USA
3Division of Pediatric Surgery, Children’s National Medical Center, Washington, DC, USA
4Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
5Division of Pulmonary and Sleep Medicine, Children’s National Medical Center, Washington, DC, USA
6Division of Emergency Medicine Children’s National Medical Center, Washington, DC, USA

Abstract

Background—Obesity is frequently complicated by comorbid conditions, yet how excess adipose contributes is poorly understood. Although adipocytes in obese individuals induce systemic inflammation via secreted cytokines, another potential mediator has recently been identified (i.e. adipocyte-derived exosomes). We hypothesized that adipocyte-derived exosomes contain mediators capable of activating end-organ inflammatory and fibrotic signaling pathways.

Methods—We developed techniques to quantify and characterize exosomes shed by adipocytes from 7 obese (age: 12–17.5 years, BMI: 33–50 kg/m²) and 5 lean (age: 11–19 years, BMI: 22–25 kg/m²) subjects.

Results—Abundant exosomal miRNAs, but no mRNAs, were detected. Comparison of obese vs. lean visceral adipose donors detected 55 differentially-expressed miRNAs (p<0.05; fold change ≥ 1.2). qRT-PCR confirmed downregulation of miR-148b (ratio = 0.2 [95% confidence interval = 0.1, 0.6]) and miR-4269 (0.3 [0.1, 0.8]), and upregulation of miR-23b (6.2 [2.2, 17.8]) and miR-4429 (3.8 [1.1 to 13.4]). Pathways analysis identified TGF-β signaling and Wnt/β-catenin signaling among the top canonical pathways expected to be altered with visceral adiposity based

*To whom correspondence should be addressed: Robert J. Freishtat, MD, MPH, Division of Emergency Medicine, Children’s National Medical Center, 111 Michigan Avenue, NW, Washington, DC 20010, rfreishtat@childrensnational.org.

Disclosures: No conflicts of interests or financial disclosures for any of the authors.
on projected mRNA targets for the 55 differentially expressed miRNAs. A select mRNA target was validated in vitro.

**Conclusion**—These data show that visceral adipocytes shed exosomal-mediators predicted to regulate key end-organ inflammatory and fibrotic signaling pathways.

**Introduction**

Obesity is a systemic inflammatory state (1) associated with chronic inflammatory and metabolic diseases impacting nearly every organ system within the body (2–4). Previous studies showed that visceral adipocytes promote systemic inflammation by secreting mediators such as interleukin (IL)-6, tumor necrosis factor (TNF)-α, and leptin, among others (5). These mediators are secreted into the circulation (5,6) and affect distant organs increasing the risk of type 2 diabetes, atherosclerosis, cardiovascular disease, asthma (4), and several forms of cancer. In addition, obesity is known to increase systemic TGF-β1 levels, which activate fibroblasts to differentiate into myofibroblasts, increasing the release of extracellular matrix proteins (7). Extracellular matrix protein accumulation can disrupt physiological organ architecture, resulting in fibrotic disease such as that seen in non-alcoholic fatty liver disease (NAFLD) (8,9).

Recently, the exosome has garnered attention as an important mediator of intercellular communication. Exosomes are actively shed endocytic vesicles that contain and transport functional mRNAs, miRNAs, and proteins between cells (10,11). In obese individuals adipocyte-derived exosomes are known to contribute to the development of insulin resistance via activation of adipose-resident macrophages and secretion of pro-inflammatory cytokines that can result in insulin resistance (12). However, exosomes may also carry pro-inflammatory factors via the circulation (13) and interact with remote cell types to promote inflammation through activation of contributory pathways (14,15). We hypothesize that visceral obese adipocytes shed exosomes that contain mediators capable of activating end-organ inflammatory and fibrotic signaling pathways.

Herein, we isolated, quantified, and characterized exosomes from surgically-acquired human visceral and subcutaneous adipose tissue from obese and lean adolescents. We isolated total exosomal RNA detecting only miRNA but not mRNA. Therefore, we profiled exosomal miRNAs focusing on obese versus lean visceral adipose expression due to the association between accumulating visceral adipose and increased cardiometabolic disease risk (5,16). miRNA profiles show downregulation of several miRNAs in obese compared to lean visceral adipocyte exosomes that target TGF-β and Wnt/β-catenin signaling, which would be expected to activate these pathways in end-organs by decreasing negative regulation of gene expression. This finding provides important insight into a direct mechanism by which obesity may mediate comorbid disease.

**Results**

**Subject demographics**

Obese (n=7) and lean (n=5) adolescents were enrolled on the day of surgery. The mean age at the time of surgery was 15.0±0.7 years (±SEM) for obese participants and 15.6±1.4 years...
for lean participants ($p = 0.70$). Obese participants had a pre-surgery mean BMI of 39.8±2.0 kg/m$^2$ and for lean participants the mean BMI was 23.2±0.5 kg/m$^2$ ($p<0.001$). All participants were female and from diverse racial backgrounds. Selected clinical characteristics are shown in Table 1.

**Macrophage Activation State in Obese and Lean Adipose**

Adipose macrophages have different activation states; pro-inflammatory (known as M1 and classically activated by interferon-$\gamma$ or lipopolysaccharide) or anti-inflammatory (known as M2 and alternatively activated by IL-13 or IL-4) (17). We characterized the activation state of infiltrating macrophages in the adipose from all participants by immunohistochemistry for M1 (i.e. CD40$^+$, a macrophage surface receptor involved in proinflammatory pathways (17,18)) and M2 (CD163$^+$ or CD206$^+$) activation states (Figure 1A). Obese visceral adipose shows a higher number of CD40$^+$ macrophages than lean visceral adipose [lean visceral (mean±SEM)=1.3±0.5 events per field (range=0.0 to 3.3), lean visceral=1.3±0.4 (0.7 to 2.3), obese visceral=3.3±0.6 (0.0 to 3.3), obese visceral=5.0±0.8 (2.7 to 8.0); comparison of lean visceral vs. obese visceral $p=0.028$] (Figure 1B). In addition, obese subcutaneous adipose showed a higher number of CD163$^+$ macrophages than lean subcutaneous adipose [obese subcutaneous=1.0±0.3 (0.3 to 2.0) vs. lean subcutaneous=0.2±0.1 (0.0 to 0.3); $p=0.04$]. No differences were found for CD206$^+$ macrophages. Consistent with previous studies (17,19), the obese visceral adipose depot showed the highest M1:M2 ratio compared to every other condition (M1:M2 ratios: Obese visceral=18.9, obese subcutaneous=4.2, lean subcutaneous=5.0, lean visceral=3.3) (Figure 1C).

**Sizing and Quantification of Adipocyte-Derived Exosomes**

We verified size for isolated adipocyte-derived exosomes using nanoparticle tracking analysis that demonstrated all vesicles were within the 50–100 nm size range. To quantify the isolated exosomes, we adapted bead-based flow cytometry approaches. We first attached PKH67 pre-labeled exosomes to latex beads via binding to the CD63 antigen, a known exosomal marker (20–22). Figure 2A depicts the principle of this technique: With increasing concentration of exosomes in a suspension, more fluorescently-labelled exosomes are bound to beads, therefore the fluorescence increases proportionally. Using the same labelling technique on known concentrations of commercially-available exosome standards, we generated a reproducible standard curve of geometric mean fluorescence intensity vs. concentration ($\mu$g/mL) (Figure 2B). The derived concentrations of exosomes isolated from lean and obese adipose are shown in Figure 2C (lean subcutaneous=10.4±0.8 $\mu$g/mL, lean visceral=16.0±1.4 $\mu$g/mL, obese subcutaneous=9.8±0.7 $\mu$g/mL, and obese visceral=11.1±0.6 $\mu$g/mL). Only lean visceral adipocyte-derived exosomes are more concentrated than obese visceral adipocyte-derived exosomes ($p \neq 0.03$). In addition, as the BMI of the donor increases, visceral adipocyte-derived exosome concentration decreases, $R^2=0.46$ (Figure 2D).

**Characterization of Adipocyte-Derived Exosomes**

Given variable resident macrophage infiltration of the adipose, it was important to verify the cellular origin of the isolated exosomes. Consequently, we chose three markers: Fatty acid...
binding protein 4 (FABP4), an adipocyte differentiation marker (23); DLK/Pref-1, a preadipocyte marker (24); and CD14, a macrophage marker (25). Lean adipocyte exosomes were almost entirely FABP4\(^{+}\) (99.7±0.001\%). In addition, many beads bound DLK/Pref-1\(^{+}\) exosomes (43.4±0.014\%). Importantly, very few exosomes were CD14\(^{+}\) (2.8±0.004\%). Similarly, obese adipocyte exosomes were also almost all FABP4\(^{+}\) (99.8±0.001\%) and CD14\(^{-}\) (96.7±0.003\%) with a similar percentage of beads binding DLK/Pref-1\(^{+}\) (47.5±0.027\%). We found no differences between conditions (Figure 3). The endothelial marker CD31 was not detected.

**Differential Expression of miRNA in Obese and Lean Visceral Exosomes**

We could detect no mRNA in isolated exosomes, before or after amplification, by either microfluidic methods or qRT-PCR for the ubiquitous housekeeping gene GAPDH. However, we did detect abundant miRNA by qRT-PCR for the endogenous control, u6snRNA. Amplified exosomal RNA was verified using a 1.5% agarose gel electrophoresis (Supplemental Figure (online)). Statistical analyses of miRNA microarray expression revealed that 88 mature miRNAs are present at significantly different levels in exosomes from obese visceral compared with lean visceral adipose (Supplemental Table 1 (online)). Ingenuity Pathways Analysis software (Ingenuity Inc., Redwood City, CA) mapped the 88 differentially expressed mature miRNAs to 55 known miRNAs based on current miRNA annotations. We found that these 55 differentially expressed mature miRNAs putatively target 7,789 mRNAs. Among the top ranked canonical pathways (Supplemental Table 2 (online)) represented by these mRNAs are TGF-\(\beta\) signaling (\(p=8.3\times10^{-10}\), number of predicted molecules targeted=54 out of 89) and Wnt/\(\beta\)-catenin signaling (\(p=4.6\times10^{-10}\), 93 out of 171 predicted molecules targeted) (Figure 4). In particular, miR-23b, miR-140-3p, miR-148b, and miR-182 are experimentally-validated to target these pathways (26) (annotated on Figure 4A).

Using qRT-PCR, we attempted to confirm the expression differences between obese and lean visceral exosomes for 7 miRNAs (i.e. miR-23b, miR-148b, miR-182, miR-3681, miR-4269, miR-4319, miR-4429) that had the highest number of experimentally-validated and/or predicted target mRNAs (i.e. ≥3) in the TGF-\(\beta\) and Wnt/\(\beta\)-catenin signaling pathways. We confirmed significant downregulation of miR-148b (ratio=0.2 [95% confidence interval=0.1, 0.6]) and miR-4269 (0.3 [0.1, 0.8]). In addition, we confirmed upregulation of miR-23b (6.2 [2.2, 17.8]) and miR-4429 (3.8 [1.1, 13.4]).

**Obese visceral adipocyte exosome uptake into lung epithelial cells**

In order to demonstrate that adipocyte-derived exosomes can influence gene expression in cells, we first showed incorporation of these exosomes into cells in vitro. Adipocyte exosome uptake into A549 cells was demonstrated after 24 hours of co-culture using PKH26 labeling of obese visceral exosomal membranes (Figure 4B). Immunofluorescent imaging demonstrates that exosome membranes become abundant within the cytoplasm of these cells.
Obese visceral adipocyte exosomes modify gene expression in A549 cells

After establishing cellular uptake of adipocyte-derived exosomes, we sought to demonstrate that exosomes could alter gene expression after 24 hours of exposure. We focused this proof-of-principle effort on expression of the activin receptor type-2B (ACVR2B) in A549 cells. ACVR2B was selected due to its importance in TGF-β signaling (27) and the fact that it is targeted by both confirmed upregulated miRNAs in our experiments: miR-23b and miR-4429. Consistent with these miRNA results, ACVR2B was significantly downregulated in the presence of obese compared to lean visceral exosomes (Fold Change<sub>obese vs. lean</sub> = 0.19 [0.16, 0.23]).

Discussion

As endocytic vesicles capable of transporting functional mRNAs, miRNAs, and proteins between cells over large distances, exosomes are a logical putative contributor to mechanisms by which adipocytes can influence other organ systems. We used novel techniques to quantify and characterize exosomes shed by surgically-acquired visceral and subcutaneous adipose from lean and obese individuals. Our exosomal content analyses showed abundant miRNAs. Due to the importance of the visceral adipose depot in obesity-related comorbidities, such as cardiovascular disease and metabolic syndrome (16), we prioritized visceral obese vs. lean comparisons. We found 55 mature miRNAs (with 7,789 confirmed or putative mRNA targets) differentially-expressed between these conditions. TGF-β and Wnt/β-catenin signaling emerged as top canonical pathways targeted by these miRNAs, 4 of which were confirmed by qRT-PCR: miR-23b, miR-148b, miR-4269, and miR-4429. Exosomal uptake by cells was confirmed in vitro along with validation of the predicted downregulation of ACVR2B in the TGF-β signaling pathway. The interaction between Wnt/β-catenin and TGF-β signaling appears to be important in the development and progression of chronic inflammation and fibrotic disease (8,28). TGF-β signaling is implicated in the appearance of extracellular matrix-secreting myofibroblasts (29,30). A recent study demonstrated that canonical Wnt signaling is necessary for TGF-β mediated fibrosis (8). Importantly, fibrotic disease can affect multiple organ systems in patients with obesity (9). Further, fat mass extension in humans is correlated with collagen deposition and fibrosis within adipose tissue, leading to systemic metabolic disturbances (31,32).

One aspect of exosome secretion addressed in our study was whether isolated exosomes were of adipocyte or macrophage origin. Previous groups demonstrated that the M1 macrophage activation state is increased in obese visceral adipose and results in the release of mediators that contribute to systemic inflammation (5) and induce insulin resistance (33). Our findings are similar to these previous studies in that visceral adipose from obese participants has higher infiltrating macrophages with M1 (CD40<sup>+</sup>) activation states. This raised the possibility that macrophage exosomes would contaminate our exosome isolation. However, we confirmed that isolated exosomes express FABP4 and not the macrophage marker CD14. The expression of FABP4 is confined almost exclusively to adipose and adipogenic cell lines, and is highly regulated during adipocyte differentiation (23).
Our finding that lean visceral adipose sheds a higher concentration of exosomes than obese visceral adipose may appear counterintuitive. On the contrary, this is actually an expected finding given that lean visceral adipose has a higher number of adipocytes and more membrane surface area per unit volume resulting in greater exosome shedding. However in an obese individual, the overall adipose volume is much greater than in lean individuals and thus the relative amount of shed adipocyte exosomes would also likely be greater. This implies that systemic circulation of adipocyte-derived exosomes would be greater in obese individuals, thus magnifying their effect on end-organ mRNA expression.

Because we profiled the contents of isolated exosomes from human adipose ex vivo, the predicted effects of adipocyte-derived exosomal miRNA on the TGF-β and Wnt/β-catenin signaling pathways are speculative. However, our data showing exosomal uptake by A549 cells in vitro along with validation of ACVR2B expression differences support this. The downregulation of ACVR2B is very interesting in that activin signaling through this receptor functions similarly to Wnt/β-catenin signaling to prevent adipogenesis (34).

To fully understand the function of adipocyte exosomal miRNAs in vivo it must be determined whether they are shed from adipose into the circulation, if they are extracted by cells in end organs, and the alterations in TGF-β and Wnt/β-catenin signaling pathways in end organs. In addition, the variability in exosome concentration in end organ tissue according to adipose mass (i.e. dose effect) will need to be clarified. Also, because we did not profile miRNA expression in the adipocytes themselves, we cannot ascertain whether exosomal miRNA differences are a function of different intracellular miRNA abundance or selective miRNA export.

In summary, there are several important findings from this study. First, the bead-based flow cytometry techniques we used to quantify exosomes are generalizable to many laboratories. Second, we show that visceral adipose sheds exosomes primarily from adipocyte, not macrophage, origin. Finally, these exosomes contain miRNAs capable of regulating end-organ TGF-β and Wnt/β-catenin signaling in obesity-related comorbid conditions. Because these same pathways are important in development, childhood obesity may result in early and cumulative epigenetic changes leading to obesity-related comorbid diseases.

Materials and Methods

Study Participants

Participants were females, 11–19 years old. Obese subjects were recruited from our adolescent bariatric surgery program and lean subjects were selected from a convenience sample of patients undergoing unrelated abdominal procedures. The clinical criterion for obesity was a BMI>30 kg/m² and for lean was a BMI<25 kg/m². Obese participants underwent a 2-week protein-sparing modified fast in the immediate period prior to surgery. All patients (both lean and obese) were fasted eight hours prior to surgery. Patients were not on any noteworthy medications. BMI was calculated from height and weight measurements taken on day of surgery for all patients. Visceral adipose was excised from the omentum and subcutaneous adipose from the anterior abdominal wall incision site. All clinical investigations were Institutional Review Board approved. Informed consent was obtained.
from participants or parental guardians. The study enrolled only female participants with age-matched lean controls in an effort to eliminate confounding effects due to sex differences, as in previously published studies (35).

**Exosome isolation**

Visceral and subcutaneous adipose samples collected from obese and lean patients intraoperatively were promptly cultured using a published protocol (12). To isolate exosomes, visceral and subcutaneous adipose tissue were washed with PBS and cut into 4 mm\(^3\) pieces, transferred to twelve-well plates containing 3 mL/well of Dulbecco's modified Eagles medium (Invitrogen, Carlsbad, CA) supplemented with 50 µg/mL gentamicin. The culture supernatant was centrifuged at 3,000g for 15 minutes to remove cells and cellular debris. Exosomes were then isolated from cultured supernatants using ExoQuick-TC Precipitation Solution (System Biosciences, Mountain View, CA) and filtered through a 200 nm filter (Sarstedt, Nümbrecht, Germany).

**Nanoparticle Tracking**

The sizes and zeta potentials of the exosomes were determined using a Zetasizer Nano ZS (Malvern Instruments Ltd, Worcestershire, UK). Sizing of exosomes was performed using a 10 µg/mL suspension of the exosomes in Milli-Q water (Millipore, Billerica, Massachusetts). Zeta potential of the exosomes was measured in Milli-Q water (Millipore, Billerica) using the Smoluchowski diffusion equation.

**Flow Cytometry**

A novel bead-based flow cytometry quantification assay was adapted from Lässer, *et al.* (21). Isolated adipocyte-derived exosomes and exosomal standards (HansaBiomed, Tallinn, Estonia) (0.6 µg, 3 µg, 4.5 µg, 6 µg, 10 µg, and 12 µg concentrations) were labeled with PKH67 Green Fluorescent Cell Linker Kit for General Cell Membrane Labeling (Sigma Aldrich, St. Louis, MO) using exosome-depleted Fetal Bovine Serum (Lonza, Walkersville, MD) (36) and bound to latex beads (Invitrogen, Carlsbad, CA) coated with anti-CD63 clone H5C6 (BD Biosciences, San Jose, CA). Data were acquired using a FACSCaliber flow cytometer and analyzed using FlowJo (TreeStar Inc., Ashland, OR).

Adipocyte-derived exosomes were characterized using the Lässer, *et al.* protocol for characterizing exosomes (21). Bead-bound exosomes were characterized using the following antibodies: Polyclonal Rabbit Anti-FABP4 (Bioss, Freiburg, Germany), Anti-CD14-PE Clone M5E2 (BD Biosciences, San Jose, CA), and Anti-DLK/Pref-1-FITC Clone 24-11 (MBL International, Woburn, MA) bound to Goat Anti-Rabbit IgG-Alexa Fluor 700 (Life Technologies, Carlsbad, CA) with appropriate isotype controls: PE Mouse IgG2αX Clone G155–178 (BD Biosciences, San Jose, CA), Rabbit Anti-IgG (antibodies-online.com, Atlanta, GA), and Rat Anti-IgG1-FITC Clone LO-DNP-1 (MBL International). We also stained for endothelial marker Anti-CD31-Alexa 488 Clone 488 Clone M89D3 (BD Biosciences, San Jose, CA) with appropriate isotype control: Mouse IgG2a, κ Alexa Fluor 488 Clone G155–178 (BD Biosciences, San Jose, CA).
**Immunohistochemistry and immunofluorescence**

Visceral and subcutaneous adipose were stained for M1 and M2 macrophages since adipose macrophage activation state (pro-inflammatory, or M1, vs. anti-inflammatory, or M2) has been shown to play a role in obesity mediated mechanisms in previous studies (17). Flash frozen visceral and subcutaneous adipose samples were cut into 5 µm sections (Histoserv, Inc., Germantown, MD) for M1:M2 Macrophage immunohistochemistry staining using a previously established protocol (17). Antibodies targeting M1 and M2 macrophages subtypes, respectively, were used: CD40 Clone 5C3 (BD Biosciences, San Jose, CA), CD206 Clone 19.2 (BD Biosciences, San Jose, CA), and CD163 Clone EDHu-1 (Abdserotec, Oxford, UK). Stained cells were counted in three sections per condition and adipose depot at 20x magnification and the mean was then calculated.

A549 cells were applied (6,500 cells/well) to 8-well Millicell EZ slides using standardized protocols (37). Cultures were proliferated in standard media (Ham’s F12, 10% FBS, and PenStrep) to 80% confluence over 24 hours. We labeled obese visceral adipocyte exosomes with PKH26 for 30 minutes followed by washes and resuspension at a final concentration of 2 µg/mL. We exposed the A549 cells to the PKH26-labeled exosomes for 24 hours. We then fixed the slides using 4% paraformaldehyde and added DAPI nuclear stain for viewing and imaging. The chamber slides and exosomes were visualized with an Olympus BX61 upright bright field/fluorescent imaging microscope (Olympus, Center Valley, PA, USA).

**RNA Extraction and Amplification**

We extracted adipocyte-exosomal total RNA using mirVana miRNA Isolation Kits (Life Technologies) and amplified total RNA with the Complete Seramir Exosome RNA Amplification Kit from Media and Urine (System Biosciences, Mountain View, CA) according to manufacturer’s instructions. A549 cellular RNA was isolated and purified using the Norgen RNA Clean-Up and Concentration Micro Kit (Norgen Biotek, Thorold, ON, Canada). We verified amplified exosomal RNA using 1.5% agarose gel electrophoresis according to manufacturer’s instructions and using appropriate validated endogenous controls for qRT-PCR (u6snRNA). We accepted samples of RNA quality determined by Nanodrop1000 (Thermo Scientific, Wilmington, DE) with absorbance ratios for UV 260/280 ≥2.0 and 260/230 between 1.8 and 2.2.

**RNA Expression, Statistical Analyses and Biological Pathway Analysis**

We used the Agilent 2100 Bioanalyzer RNA Pico Chip (Agilent Technologies, Santa Clara, CA) and TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA) for detection of GAPDH mRNA. We used TaqMan Small RNA Assays (Invitrogen, Life Technologies, Carlsbad, CA) to verify u6snRNA expression. We labeled RNA with Affymetrix® FlashTag™ Biotin HSR RNA Labeling Kit (Affymetrix, Santa Clara, CA) and ran according to standard procedures. Labeled RNA was hybridized to Affymetrix GeneChip miRNA 3.0 arrays which were run using the Fluidics Station 450 Protocol (FS450_002) (Affymetrix, Santa Clara, CA). Resulting data were analyzed in Expression Console using RMA+DMBG (Affymetrix) and then exported it to Partek Genomics Suite for analyses. Only mature human miRNAs (N=1,733) were retained for statistical comparison between groups (as the Affymetrix 3.0 miRNA arrays contain miRNA from
multiple species). Three-factor ANCOVA (ID*group (lean vs. obese)*adipose depot; with age covariate) was used to compare miRNA expression, using unadjusted p ≤ 0.05 and fold change ≥ 1.2 as filters. Main effects for group (obesity-state) and tissue depot were generated along with their interaction term. As a part of the overall ANCOVA, specific within-group (depot effects within obese or lean) and within-tissue (obesity effects within depot) contrasts were used. Given the relatively small number of comparisons for array analyses, we did not use a False Discovery Rate cutoff, as the purpose of this initial scan was to generate a robust list for pathway analysis (in which Type I or false positive results are minimized given the improbability of finding related elements as independent errors). Instead, we used lower cutoffs within downstream pathway analyses.

In Ingenuity Pathways Analysis software (Ingenuity Inc., Redwood City, CA), predicted targets were generated from significantly dysregulated miRNAs. First, significant miRNAs were uploaded from ANCOVA into Ingenuity Pathways Analysis software (Ingenuity Inc., Redwood City, CA). These were processed by Ingenuity’s miRNA Target Filter analysis tool, generating target mRNA lists from only experimentally verified or highly conservative predicted targets (a stringent cutoff). Resultant mRNA lists were analyzed for the representation of common biological pathways using Ingenuity’s core analysis function and a stringent cutoff for pathway representation at p ≤ 0.01.

Data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series accession numbers GSE50574 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50574), and GSE54606 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=mpqlimievtsfbob&acc=GSE54606).

qRT-PCR

The Individual MicroRNA Assays (Life Technologies, Carlsbad, CA) used for confirmation were: miR-23b, miR-148b, miR-4269, and miR-4429. Specifications for the TaqMan MicroRNA Assays include: TaqMan MicroRNA Reverse Transcription Kit (Life Technologies, Carlsbad, CA), TaqMan PreAmp Master Mix (2x) (Life Technologies, Carlsbad, CA), and the TaqMan Universal Master Mix II, No AmpErase UNG (2x) (Life Technologies, Carlsbad, CA).

A549 cellular RNA was processed with the High Capacity cDNA Reverse Transcription Kit (Life Technologies, Carlsbad, CA), TaqMan® Gene Expression Master Mix (Life Technologies, Carlsbad, CA), and the TaqMan® Gene Expression Assays for ACVR2B and GAPDH (endogenous control) (Life Technologies, Carlsbad, CA). All miRNA and mRNA results were analyzed with SDS (Applied 7900HT Fast Real-Time PCR System, Life Technologies) and Microsoft Excel 2013 (Microsoft Corporation, Redmond, WA).

Data and materials availability—The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series accession number GSE50574 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50574).
Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Statement of financial support: This project was supported by grants R01MD007075 and UL1TR000075 to RJF and by grant K12HD001399 to DKP from the National Institutes of Health, Bethesda, MD. Additional support was provided to RJF by the Clark Charitable Foundation, Bethesda, MD.

References

1. Xu H, Barnes GT, Yang Q, et al. Chronic Inflammation in Fat Plays a Crucial Role in the Development of Obesity-Related Insulin Resistance. J Clin Invest. 2003; 112:1821–1830. [PubMed: 14679177]
2. Lumeng CN, Saltiel AR. Inflammatory Links between Obesity and Metabolic Disease. J Clin Invest. 2011; 121:2111–2117. [PubMed: 21633179]
3. Jensen ME, Gibson PG, Collins CE, Wood LG. Airway and Systemic Inflammation in Obese Children with Asthma. Eur Respir J. 2013; 42:1012–1019. [PubMed: 23349447]
4. de Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL, group Ps. Obesity and Target Organ Damage: The Kidney. Int J Obes Relat Metab Disord. 2002; 26(Suppl 4):S21–S24. [PubMed: 12457295]
5. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral Fat Adipokine Secretion Is Associated with Systemic Inflammation in Obese Humans. Diabetes. 2007; 56:1010–1013. [PubMed: 17287468]
6. Fain JN, Tichansky DS, Madan AK. Transforming Growth Factor Beta Release by Human Adipose Tissue Is Enhanced in Obesity. Metabolism. 2005; 54:1546–1551. [PubMed: 16253647]
7. Masszi A, Fan L, Rosivall L, et al. Integrity of Cell-Cell Contacts Is a Critical Regulator of Tgf-Beta 1-Induced Epithelial-to-Myofibroblast Transition: Role for Beta-Catenin. Am J Pathol. 2004; 165:1955–1967. [PubMed: 15579439]
8. Akhmetshina A, Palumbo K, Dees C, et al. Activation of Canonical Wnt Signalling Is Required for Tgf-Beta-Mediated Fibrosis. Nat Commun. 2012; 3:735. [PubMed: 22415826]
9. Fujii H, Kawada N. Inflammation and Fibrogenesis in Steatohepatitis. J Gastroenterol. 2012; 47:215–225. [PubMed: 22310735]
10. Camussi G, Deregibus MC, Bruno S, Grange C, Fonsato V, Tetta C. Exosome/Microvesicle-Mediated Epigenetic Reprogramming of Cells. Am J Cancer Res. 2011; 1:98–110. [PubMed: 21969178]
11. Zernecke A, Bidzhekov K, Noels H, et al. Delivery of Microrna-126 by Apoptotic Bodies Induces Cxc12-Dependent Vascular Protection. Sci Signal. 2009; 2:ra81. [PubMed: 19996457]
12. Deng ZB, Poliakov A, Hardy RW, et al. Adipose Tissue Exosome-Like Vesicles Mediate Activation of Macrophage-Induced Insulin Resistance. Diabetes. 2009; 58:2498–2505. [PubMed: 19675137]
13. Ardoin SP, Shanahan JC, Pisetsky DS. The Role of Microparticles in Inflammation and Thrombosis. Scand J Immunol. 2007; 66:159–165. [PubMed: 17635793]
14. Lasser C, Alikhani VS, Ekstrom K, et al. Human Saliva, Plasma and Breast Milk Exosomes Contain Rna: Uptake by Macrophages. J Transl Med. 2011; 9:9. [PubMed: 21235781]
15. Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/Microvesicles as a Mechanism of Cell-to-Cell Communication. Kidney Int. 2010; 78:838–848. [PubMed: 20703216]
16. Kishida K, Funahashi T, Matsuzawa Y, Shimomura I. Visceral Adiposity as a Target for the Management of the Metabolic Syndrome. Ann Med. 2012; 44:233–241. [PubMed: 21612331]
17. Aron-Wisnewsky J, Tordjman J, Poitou C, et al. Human Adipose Tissue Macrophages: M1 and M2 Cell Surface Markers in Subcutaneous and Omental Depots and after Weight Loss. J Clin Endocrinol Metab. 2009; 94:4619–4623. [PubMed: 19837929]
18. Imaizumi K, Kawabe T, Ichiyama S, et al. Enhancement of Tumoricidal Activity of Alveolar Macrophages Via Cd40-Cd40 Ligand Interaction. Am J Physiol. 1999; 277:L49–L57. [PubMed: 10409230]

19. Fujisaka S, Usui I, Bukhari A, et al. Regulatory Mechanisms for Adipose Tissue M1 and M2 Macrophages in Diet-Induced Obese Mice. Diabetes. 2009; 58:2574–2582. [PubMed: 19690061]

20. Mathivanan S, Ji H, Simpson RJ. Exosomes: Extracellular Organelles Important in Intercellular Communication. J Proteomics. 2010; 73:1907–1920. [PubMed: 20601276]

21. Lasser C, Eldh M, Lotvall J. Isolation and Characterization of Rna-Containing Exosomes. J Vis Exp. 2012:e3037. [PubMed: 22257828]

22. Feverri B, Raposo G. Exosomes: Endosomal-Derived Vesicles Shipping Extracellular Messages. Curr Opin Cell Biol. 2004; 16:415–421. [PubMed: 15261674]

23. Shan T, Liu W, Kuang S. Fatty Acid Binding Protein 4 Expression Marks a Population of Adipocyte Progenitors in White and Brown Adipose Tissues. FASEB J. 2013; 27:277–287. [PubMed: 23047894]

24. Wang Y, Kim K-A, Kim J-H, Sul H. Pref-1, a Preadipocyte Secreted Factor That Inhibits Adipogenesis. J Nutr. 2006; 136:2953–2956. [PubMed: 17116701]

25. Khazen W, M’Bika JP, Tomkiewicz C, et al. Expression of Macrophage-Selective Markers in Human and Rodent Adipocytes. FEBS Lett. 2005; 579:5631–5634. [PubMed: 16213494]

26. Kozomara A, Griffiths-Jones S. Mirbase: Integrating Microrna Annotation and Deep-Sequencing Data. Nucleic Acids Res. 2011; 39:D152–D157. [PubMed: 21037258]

27. Santibanez JF, Quintanilla M, Bernabeu C. Tgf-Beta/Tgf-Beta Receptor System and Its Role in Physiological and Pathological Conditions. Clinical science. 2011; 121:233–251. [PubMed: 21615335]

28. Henderson WR, Chi EY, Ye X, et al. Inhibition of Wnt/B-Catenin/Creb Binding Protein (Cbp) Signaling Reverses Pulmonary Fibrosis. Proceedings of the National Academy of Sciences. 2010; 107:14309–14314.

29. Zavadil J, Bottinger EP. Tgf-Beta and Epithelial-to-Mesenchymal Transitions. Oncogene. 2005; 24:5764–5774. [PubMed: 16123809]

30. Hinz B. Formation and Function of the Myofibroblast During Tissue Repair. J Invest Dermatol. 2007; 127:526–537. [PubMed: 17299435]

31. Divoux A, Tordjman J, Lacasa D, et al. Fibrosis in Human Adipose Tissue: Composition, Distribution, and Link with Lipid Metabolism and Fat Mass Loss. Diabetes. 2010; 59:2817–2825. [PubMed: 20713683]

32. Spencer M, Yao-Borengasser A, Unal R, et al. Adipose Tissue Macrophages in Insulin-Resistant Subjects Are Associated with Collagen Vi and Fibrosis and Demonstrate Alternative Activation. Am J Physiol Endocrinol Metab. 2010; 299:E1016–E1027. [PubMed: 20841504]

33. Lacasa D, Taleb S, Keophiphath M, Miranville A, Clement K. Macrophage-Secreted Factors Impair Human Adipogenesis: Involvement of Proinflammatory State in Preadipocytes. Endocrinology. 2007; 148:868–877. [PubMed: 17082259]

34. Sethi JK. Activatin’human Adipose Progenitors in Obesity. Diabetes. 2010; 59:2354–2357. [PubMed: 20876727]

35. Henry Buchwald RE, Fahrbach Kyle, Banel Deirdre, Jensen Michael D, Pories Walter J, Bantle John P, Sledge Isabella. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-Analysis. The American Journal of Medicine. 122:248–256. [PubMed: 19272486]

36. Xiang X, Poliakov A, Liu C, et al. Induction of Myeloid-Derived Suppressor Cells by Tumor Exosomes. Int J Cancer. 2009; 124:2621–2633. [PubMed: 19235923]

37. Freishtat RJ, Watson AM, Benton AS, et al. Asthmatic Airway Epithelium Is Intrinsically Inflammatory and Mitotically Dyssynchronous. Am J Respir Cell Mol Biol. 2011; 44:863–869. [PubMed: 20705942]
Figure 1. M1:M2 Macrophage immunohistochemistry of adipose tissues

(A) Frozen sections of adipose from visceral and subcutaneous (SQ) depots were stained for CD40 (M1), CD206 (M2), and CD163 (M2), in 7 obese and 5 lean individuals. Representative samples are shown at 20× magnification.

(B) Obese visceral adipose shows a higher number of CD40+ macrophages than lean visceral adipose. In addition, obese subcutaneous adipose has a higher number of CD163+ macrophages than lean subcutaneous adipose. No significant differences were found for CD206+ macrophages. *P-values <0.05 determined by a two-sided Student’s t-test; error bars represent ±SEM; key: ■Lean SQ, □Lean Visceral, Obese SQ, Obese Visceral.

(C) The obese visceral adipose depot showed the highest M1:M2 ratio compared to every other condition.
Figure 2. Quantification of adipocyte-derived exosomes using bead-based flow cytometry

(A) Depiction of the bead-based flow cytometry technique: Increasing exosomal concentration results in increased number of exosomes attached to beads, therefore proportionally increasing geometric mean fluorescence intensity of PKH67 staining.

(B) Generated standard curve and coefficient of determination of commercially available exosomal standards (R²=0.87).

(C) Concentration of isolated exosomes from a standardized starting amount of obese (n=7) and lean (n=5) adipose. Lean visceral adipocyte-derived exosomes are significantly more
concentrated than those from obese visceral adipose. *P-value<0.05 determined by a two-sided Student’s t-test; error bars represent ±SEM.

(D) As BMI increases, visceral adipocyte-derived exosome concentration decreases (R²=0.46).
Figure 3. Flow cytometry characterization of adipocyte-derived exosomes

Isolated exosomes from both visceral and subcutaneous depots were characterized for FABP4, Pref-1, and CD14.

(A) Representative flow cytometry for FABP4, Pref-1, and CD14 in adipocyte-derived exosomes from a lean subcutaneous sample.

(B) Lean adipocyte exosomes (n=5) were almost all FABP4⁺. In addition, many beads bound DLK/Pref-1⁺ exosomes. Very few beads bound CD14⁺ exosomes. Obese adipocyte exosomes (n=7) were also almost all FABP4⁺ with a similar percentage of beads binding DLK/Pref-1⁺ and/or CD14⁺ exosomes. No differences in marker expression were found between conditions determined by a two-sided Student’s t-test; error bars represent ±SEM; key: □ Lean, ☐ Obese.
Figure 4. Combined Wnt/β-catenin and TGF-β signaling pathways and validation
(A) The two canonical pathways were among the top ranked as determined by Ingenuity Pathways Analysis software (Ingenuity Inc., Redwood City, CA). Green indicates predicted downregulation of target transcripts by differentially expressed miRNAs, and red indicates predicted upregulation. Among the altered miRNAs, miR-23b, miR-140-3p, miR-148b, and miR-182 are experimentally-validated (annotated with ◆) to target members of the combined pathway.
(B) Adipocyte exosomal membranes were labeled with PKH26 (red) and co-incubated with A549 cells (nuclei stained blue with DAPI) for 24 hours. Intracellular PKH26 demonstrates exosomal uptake into A549 cells.
### Table

Demographics of patients enrolled in study

| Age (years) | Sex | BMI | Race            |
|-------------|-----|-----|-----------------|
| Lean        |     |     |                 |
| 11          | F   | 22  | Hispanic        |
| 13          | F   | 22  | Hispanic        |
| 17          | F   | 24  | White           |
| 18          | F   | 23  | African American|
| 19          | F   | 25  | African American|
| Obese       |     |     |                 |
| 12          | F   | 49  | African American|
| 13          | F   | 33  | Hispanic        |
| 14          | F   | 40  | White           |
| 15.5        | F   | 39  | African American|
| 16          | F   | 43  | African American|
| 17          | F   | 35  | Hispanic        |
| 17.5        | F   | 50  | African American|